课题基金 / 基金详情

Discovery and Mechanism of Antiretroviral Factors

Discovery and Mechanism of Antiretroviral Factors
抗逆转录病毒因子的发现及其机制
批准号:
8882713
负责人:
Paul D. Bieniasz
金额:
$58.21万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-01 至 2017-01-31

项目摘要

项目成果

Paul D. Bieniasz的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We have succeeded in identifying a number of genes with antiretroviral activity, and the continuation of this project will naturally progress with a detailed examination of the mechanism of action of one validated restriction factor (Mx2) in Aim 1, and a more broadly based follow up of additional hits, as well as additional ISG screening in Aim 2. In Aim 1 we will build on our discovery that Mx2 is an antiretroviral protein by determining its mechanism of action. Mx2 inhibits HIV-1 infection in a capsid dependent manner at a step between reverse transcription and integration. A few potential mechanisms might underlie this activity. First, Mx2 might directly target the incoming viral capsid, in a manner akin to the TRIM5a and Fvl antiretroviral proteins Crucially, we have found a number of amino acids in CA that when mutated confer resistance to Mx2 antiviral activity. These will serve as key specificity controls in our binding and core-fate assays. Additionally, we will determine whether Mx2 binds to nuclear transport components, whether the nature of the Mx2 nuclear targeting signal is important for its antiviral activity and whether the route taken by HIV-1 into the nucleus affects its susceptibility to Mx2. Ultimately these experiments should determine how Mx2 functions and whether capsid recognition and/or specific nuclear entry pathway occlusion is responsible. Our ISG screening platform has revealed numerous (-30) candidate antiretroviral proteins that either protect cells from infection, or reduce the yield of infectious virons from ISG expressing cells. Currently, our analysis of these hits is at various stages of follow up. In Aim 2 we will follow the same paths exemplified by our previous work on Mx2 and CNP. Ultimately, we will aim to determine precisely how these ISGs inhibit reroviral replication, and crucially whether they are required for the full antiviral activity of interferon. Finally, we are screening additional ISGs that were not present in our originally constructed libraries. Again the path taken by these studies will mirror our previously successful approaches. RELEVANCE (See instructions): Mammals, including humans, have an array of antiviral defense mechanisms. The mechanism by which these antiviral defenses work is only beginning to be understood. Identifying and understanding the mechanism of action of antiretroviral gene products could lead to completely new chemotherapeutic strategies for tackling infectious diseases, including AIDS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Broad neutralization of pandemic threat coronaviruses
  • 批准号:
    10327989
  • 项目类别:
  • 资助金额:
    $642.33万
  • 财政年份:
    2022
  • 负责人:
    Paul D. Bieniasz
  • 依托单位:
Broad neutralization of pandemic threat coronaviruses
  • 批准号:
    10841237
  • 项目类别:
  • 资助金额:
    $425.9万
  • 财政年份:
    2022
  • 负责人:
    Paul D. Bieniasz
  • 依托单位:
Effects of Interferon on primate lentiviruses
  • 批准号:
    10619797
  • 项目类别:
  • 资助金额:
    $71.01万
  • 财政年份:
    2022
  • 负责人:
    Paul D. Bieniasz
  • 依托单位:
Effects of Interferon on primate lentiviruses
  • 批准号:
    10708965
  • 项目类别:
  • 资助金额:
    $70.56万
  • 财政年份:
    2022
  • 负责人:
    Paul D. Bieniasz
  • 依托单位:
海外基金